Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Pancreas ; 51(4): 305-309, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35775638

ABSTRACT

OBJECTIVES: Pancreatic intraepithelial neoplasia (PanIN) is the currently preferred designation for putative preneoplastic changes in the pancreas. There are few data for the incidence of PanIN in the general population. Our goal was to determine the incidence of PanIN in a large group of pancreases obtained at autopsy. METHODS: Slides stained with hematoxylin and eosin were scanned to count PanIN. RESULTS: We found multiple PanINs in most pancreases and at least 1 in 86.4% of 154 pancreases when multiple slides (8-12) from each were examined. The average age at autopsy was 62 years, and 90% of the patients were 40 years or older. Several questions were raised by our observations. Should a minimum size be defined for classification as PanIN? Do PanINs occur in lesions that apparently arise from acinar to ductal metaplasia? Does squamous metaplasia in PanIN have any special significance, and do purely squamous lesions have preneoplastic significance? CONCLUSIONS: We conclude that the incidence of PanIN is higher than previously reported.


Subject(s)
Carcinoma in Situ , Carcinoma, Squamous Cell , Pancreatic Neoplasms , Autopsy , Carcinoma in Situ/epidemiology , Humans , Incidence , Metaplasia/epidemiology , Pancreatic Neoplasms/epidemiology
3.
Am J Pathol ; 189(1): 6-8, 2019 01.
Article in English | MEDLINE | ID: mdl-30558724

ABSTRACT

This Guest Editorial introduces this month's special Pancreatic Cancer Theme Issue, a series of reviews intended to highlight the pathologic to molecular profiles and diagnoses of benign and neoplastic pancreatic lesions.


Subject(s)
Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Humans
4.
Pancreatology ; 17(2): 263-266, 2017.
Article in English | MEDLINE | ID: mdl-28215485

ABSTRACT

OBJECTIVES: Concurrent intraductal papillary-mucinous neoplasm (IPMN) and autoimmune pancreatitis (AIP) was observed in a patient (index case) at our institution. Cases of coincidental IPMN and type 1 AIP and concurrent ductal adenocarcinoma (PDAC) and AIP have been previously reported. In this study we evaluate the hypothesis that IPMN elicits an IgG4 response. METHODS: Twenty-one pancreases (including the index case) with IPMN resected at our institution were studied. H&E stained slides were reviewed and blocks of peritumoral pancreas were immunostained with IgG4 to look for IgG4-positive plasma cells. RESULTS: We found evidence of variable IgG4 overexpression in 4/21 (19%) of IPMN. These included the index case and three others without stigmata of AIP. CONCLUSION: A small subset of pancreatic neoplasms including intraductal papillary-mucinous neoplasms (IPMN) is associated with an IgG4 autoimmune response that sometimes progresses to peritumoral type 1 AIP and less often to diffuse AIP and IgG4-related systemic disease.


Subject(s)
Adenocarcinoma, Mucinous/pathology , Autoimmune Diseases/immunology , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Papillary/pathology , Immunoglobulin G/blood , Pancreatitis/immunology , Adenocarcinoma, Mucinous/complications , Adenocarcinoma, Mucinous/immunology , Autoimmune Diseases/pathology , Carcinoma, Pancreatic Ductal/complications , Carcinoma, Pancreatic Ductal/immunology , Carcinoma, Papillary/complications , Carcinoma, Papillary/immunology , Humans , Male , Middle Aged , Pancreatitis/complications , Pancreatitis/pathology
5.
Am J Surg Pathol ; 39(12): 1730-41, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26559377

ABSTRACT

International experts met to discuss recent advances and to revise the 2004 recommendations for assessing and reporting precursor lesions to invasive carcinomas of the pancreas, including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm, and other lesions. Consensus recommendations include the following: (1) To improve concordance and to align with practical consequences, a 2-tiered system (low vs. high grade) is proposed for all precursor lesions, with the provision that the current PanIN-2 and neoplasms with intermediate-grade dysplasia now be categorized as low grade. Thus, "high-grade dysplasia" is to be reserved for only the uppermost end of the spectrum ("carcinoma in situ"-type lesions). (2) Current data indicate that PanIN of any grade at a margin of a resected pancreas with invasive carcinoma does not have prognostic implications; the clinical significance of dysplasia at a margin in a resected pancreas with IPMN lacking invasive carcinoma remains to be determined. (3) Intraductal lesions 0.5 to 1 cm can be either large PanINs or small IPMNs. The term "incipient IPMN" should be reserved for lesions in this size with intestinal or oncocytic papillae or GNAS mutations. (4) Measurement of the distance between an IPMN and invasive carcinoma and sampling of intervening tissue are recommended to assess concomitant versus associated status. Conceptually, concomitant invasive carcinoma (in contrast with the "associated" group) ought to be genetically distinct from an IPMN elsewhere in the gland. (5) "Intraductal spread of invasive carcinoma" (aka, "colonization") is recommended to describe lesions of invasive carcinoma invading back into and extending along the ductal system, which may morphologically mimic high-grade PanIN or even IPMN. (6) "Simple mucinous cyst" is recommended to describe cysts >1 cm having gastric-type flat mucinous lining at most minimal atypia without ovarian-type stroma to distinguish them from IPMN. (7) Human lesions resembling the acinar to ductal metaplasia and atypical flat lesions of genetically engineered mouse models exist and may reflect an alternate pathway of carcinogenesis; however, their biological significance requires further study. These revised recommendations are expected to improve our management and understanding of precursor lesions in the pancreas.


Subject(s)
Pancreatic Neoplasms/classification , Pancreatic Neoplasms/pathology , Precancerous Conditions/classification , Precancerous Conditions/pathology , Terminology as Topic , Biopsy , Carcinoma in Situ/chemistry , Carcinoma in Situ/pathology , Carcinoma, Pancreatic Ductal/chemistry , Carcinoma, Pancreatic Ductal/pathology , Consensus , Cooperative Behavior , Humans , International Cooperation , Neoplasm Grading , Neoplasm Invasiveness , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Neoplasms, Cystic, Mucinous, and Serous/pathology , Predictive Value of Tests , Tumor Burden
6.
Pancreas ; 43(8): 1143-62, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25333398

ABSTRACT

The diagnosis of chronic pancreatitis remains challenging in early stages of the disease. This report defines the diagnostic criteria useful in the assessment of patients with suspected and established chronic pancreatitis. All current diagnostic procedures are reviewed, and evidence-based statements are provided about their utility and limitations. Diagnostic criteria for chronic pancreatitis are classified as definitive, probable, or insufficient evidence. A diagnostic (STEP-wise; survey, tomography, endoscopy, and pancreas function testing) algorithm is proposed that proceeds from a noninvasive to a more invasive approach. This algorithm maximizes specificity (low false-positive rate) in subjects with chronic abdominal pain and equivocal imaging changes. Furthermore, a nomenclature is suggested to further characterize patients with established chronic pancreatitis based on TIGAR-O (toxic, idiopathic, genetic, autoimmune, recurrent, and obstructive) etiology, gland morphology (Cambridge criteria), and physiologic state (exocrine, endocrine function) for uniformity across future multicenter research collaborations. This guideline will serve as a baseline manuscript that will be modified as new evidence becomes available and our knowledge of chronic pancreatitis improves.


Subject(s)
Pancreatitis, Chronic/diagnosis , Calcinosis/diagnosis , Calcinosis/pathology , Cholangiopancreatography, Magnetic Resonance , Chymotrypsin/analysis , Diagnosis, Differential , Disease Progression , Endoscopy, Digestive System , Endosonography , Evidence-Based Medicine , Feces/enzymology , Humans , Incidence , Pancreatic Elastase/analysis , Pancreatic Function Tests , Pancreatic Neoplasms/diagnosis , Pancreatitis, Alcoholic/epidemiology , Pancreatitis, Chronic/epidemiology , Pancreatitis, Chronic/etiology , Pancreatitis, Chronic/pathology , Pancreatitis, Chronic/physiopathology , Risk Factors , Secretin , Sensitivity and Specificity , Severity of Illness Index , Smoking/adverse effects , Steatorrhea/etiology , Tomography, X-Ray Computed
7.
Dev Cell ; 23(6): 1203-18, 2012 Dec 11.
Article in English | MEDLINE | ID: mdl-23237953

ABSTRACT

Fenestral and stomatal diaphragms are endothelial subcellular structures of unknown function that form on organelles implicated in vascular permeability: fenestrae, transendothelial channels, and caveolae. PV1 protein is required for diaphragm formation in vitro. Here, we report that deletion of the PV1-encoding Plvap gene in mice results in the absence of diaphragms and decreased survival. Loss of diaphragms did not affect the fenestrae and transendothelial channels formation but disrupted the barrier function of fenestrated capillaries, causing a major leak of plasma proteins. This disruption results in early death of animals due to severe noninflammatory protein-losing enteropathy. Deletion of PV1 in endothelium, but not in the hematopoietic compartment, recapitulates the phenotype of global PV1 deletion, whereas endothelial reconstitution of PV1 rescues the phenotype. Taken together, these data provide genetic evidence for the critical role of the diaphragms in fenestrated capillaries in the maintenance of blood composition.


Subject(s)
Blood Proteins/metabolism , Capillaries/physiology , Capillaries/ultrastructure , Capillary Permeability , Carrier Proteins/metabolism , Endothelium, Vascular/physiology , Endothelium, Vascular/ultrastructure , Membrane Proteins/metabolism , Animals , Carrier Proteins/genetics , Caveolae/physiology , Cell Membrane/metabolism , Endothelium, Vascular/cytology , Membrane Proteins/genetics , Mice , Mice, Transgenic , Protein-Losing Enteropathies/physiopathology
8.
Exp Mol Pathol ; 93(3): 345-9, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22902940

ABSTRACT

Mucinous cystic neoplasms (MCN) and intraductal papillary mucinous neoplasms (IPMN) of the pancreas both appear to have been included and intermixed in some early reports of pancreatic cystic neoplasms. Recognition of their distinguishing features evolved during the last decade of the twentieth century. One legacy of the early period is the statement that mucinous cystic neoplasms sometimes progress to invasive colloid carcinoma. It is now recognized that colloid carcinomas characteristically arise from IPMN. We set out to see if we could find MCN that invaded as colloid carcinomas and found no examples in MCN collected in two academic medical centers. We then sought to expand the number of MCN by evaluating series from additional centers. This yielded no examples of colloid carcinomas associated with 291 MCN, however one MCN exhibited a minor component with colloid (non-cystic mucinous) growth pattern within the fibrous wall of the neoplasm. The expression of CDX2, a marker of intestinal differentiation that is found in colloid carcinomas was examined by immunostaining in the original MCN series and in the MCN with the intratumoral colloid growth pattern. Focal expression of CDX2 was found in 22 of 43 MCN including the MCN that exhibited the intratumoral colloid growth pattern. Overall, the data suggest that MCN rarely, if ever, invade as colloid carcinoma but the expression of CDX2 by some MCN and the observation of intratumoral colloid growth pattern in one MCN seems to leave open the possibility that MCN might rarely invade as colloid carcinoma. The majority of malignant MCN invade with a tubular (ductal) pattern, and rarely the invasive component was anaplastic.


Subject(s)
Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Papillary/pathology , Carcinoma, Pancreatic Ductal/pathology , Pancreatic Neoplasms/pathology , Adenocarcinoma, Mucinous/metabolism , Adenocarcinoma, Papillary/metabolism , Adult , Aged , Biomarkers, Tumor/metabolism , CDX2 Transcription Factor , Carcinoma, Pancreatic Ductal/metabolism , Female , Homeodomain Proteins/metabolism , Humans , Male , Middle Aged , Neoplasm Invasiveness , Pancreatic Neoplasms/metabolism , Young Adult
9.
J Cell Mol Med ; 16(11): 2690-700, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22568538

ABSTRACT

PV1 is an endothelial-specific protein with structural roles in the formation of diaphragms in endothelial cells of normal vessels. PV1 is also highly expressed on endothelial cells of many solid tumours. On the basis of in vitro data, PV1 is thought to actively participate in angiogenesis. To test whether or not PV1 has a function in tumour angiogenesis and in tumour growth in vivo, we have treated pancreatic tumour-bearing mice by single-dose intratumoural delivery of lentiviruses encoding for two different shRNAs targeting murine PV1. We find that PV1 down-regulation by shRNAs inhibits the growth of established tumours derived from two different human pancreatic adenocarcinoma cell lines (AsPC-1 and BxPC-3). The effect observed is because of down-regulation of PV1 in the tumour endothelial cells of host origin, PV1 being specifically expressed in tumour vascular endothelial cells and not in cancer or other stromal cells. There are no differences in vascular density of tumours treated or not with PV1 shRNA, and gain and loss of function of PV1 in endothelial cells does not modify either their proliferation or migration, suggesting that tumour angiogenesis is not impaired. Together, our data argue that down-regulation of PV1 in tumour endothelial cells results in the inhibition of tumour growth via a mechanism different from inhibiting angiogenesis.


Subject(s)
Adenocarcinoma/genetics , Adenocarcinoma/pathology , Carrier Proteins/genetics , Membrane Proteins/genetics , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Adenocarcinoma/blood supply , Animals , Base Sequence , Carrier Proteins/metabolism , Cell Line, Tumor , Cell Movement/genetics , Down-Regulation , Drug Screening Assays, Antitumor , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Gene Expression Regulation, Neoplastic , Humans , Lentivirus/genetics , Membrane Proteins/metabolism , Mice , Mice, Knockout , Mice, Nude , Molecular Sequence Data , Neovascularization, Pathologic/genetics , Pancreatic Neoplasms/blood supply , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , RNA, Small Interfering/pharmacology , Stromal Cells/metabolism , Stromal Cells/pathology
10.
PLoS One ; 6(11): e27725, 2011.
Article in English | MEDLINE | ID: mdl-22140463

ABSTRACT

Targeting of oncogenic Kras to the pancreatic Nestin-expressing embryonic progenitor cells and subsequently to the adult acinar compartment and Nestin-expressing cells is sufficient for the development of low grade pancreatic intraepithelial neoplasia (PanIN) between 2 and 4 months. The mice die around 6 month-old of unrelated causes, and it is therefore not possible to assess whether the lesions will progress to carcinoma. We now report that two brief episodes of caerulein-induced acute pancreatitis in 2 month-old mice causes rapid PanIN progression and pancreatic ductal adenocarcinoma (PDAC) development by 4 months of age. These events occur with similar frequency as observed in animals where the oncogene is targeted during embryogenesis to all pancreatic cell types. Thus, these data show that oncogenic Kras-driven PanIN originating in a non-ductal compartment can rapidly progress to PDAC when subjected to a brief inflammatory insult.


Subject(s)
Cell Lineage , Disease Progression , Intermediate Filament Proteins/metabolism , Nerve Tissue Proteins/metabolism , Pancreatic Neoplasms/pathology , Pancreatitis/pathology , Precancerous Conditions/pathology , Proto-Oncogene Proteins p21(ras)/metabolism , Animals , Carcinoma in Situ/pathology , Carcinoma, Pancreatic Ductal/metabolism , Carcinoma, Pancreatic Ductal/pathology , Ceruletide , Gene Targeting , Humans , Integrases/metabolism , Mice , Mice, Transgenic , Nestin , Pancreatic Ducts/metabolism , Pancreatic Ducts/pathology , Pancreatic Neoplasms/metabolism , Pancreatitis/metabolism , Precancerous Conditions/metabolism , STAT3 Transcription Factor/metabolism , Stem Cells/metabolism , Transgenes/genetics
11.
Pancreas ; 40(8): 1172-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21975436

ABSTRACT

OBJECTIVES: To develop and validate histologic diagnostic criteria for autoimmune pancreatitis (AIP) and its types. METHODS: Thirteen pathologists participated in this 2-phase study to develop diagnostic criteria for AIP types 1 and 2 (phase 1) and validate them (phase 2). A virtual library of 40 resected pancreata with AIP and other forms of chronic pancreatitis (CP) was constructed. Readers reviewed the slides online and filled out a questionnaire for histopathologic findings and diagnosis. RESULTS: Diagnostic criteria for AIP and its types were proposed according to the results from the top 5 reviewers in phase 1. The interobserver agreement was significantly improved in phase 2 by applying the proposed diagnostic criteria. Features distinguishing AIP from alcoholic and obstructive forms of CP were periductal lymphoplasmacytic infiltrate, inflamed cellular stroma with storiform fibrosis, obliterative phlebitis, and granulocytic epithelial lesions. Although there was overlap, 2 types of AIP were recognized. Type 1 had dense lymphoplasmacytic infiltrate with storiform fibrosis and obliterative phlebitis, whereas type 2 was distinguished from type 1 by the presence of granulocytic epithelial lesions. CONCLUSIONS: Autoimmune pancreatitis can be distinguished from other forms of CP with substantial interobserver agreement. The 2 types of AIP can be distinguished by the proposed consensus histopathologic diagnostic criteria.


Subject(s)
Autoimmune Diseases/diagnosis , Pancreas/pathology , Pancreatitis/diagnosis , Pathology, Clinical/methods , Autoimmune Diseases/classification , Autoimmune Diseases/immunology , Consensus , Diagnosis, Differential , Humans , Immunoglobulin G/analysis , Immunohistochemistry , International Cooperation , Pancreas/immunology , Pancreatitis/classification , Pancreatitis/immunology , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/immunology , Plasma Cells/immunology , Plasma Cells/pathology , Reproducibility of Results , Sensitivity and Specificity
12.
Gastroenterology ; 141(3): 1091-101, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21699781

ABSTRACT

BACKGROUND & AIMS: Rb1 encodes a cell-cycle regulator that is functionally disrupted in most human cancers. Pancreatic ductal adenocarcinomas (PDACs) have a high frequency of mutations in KRAS and INK4A/CDKN2A that might allow cells to bypass the regulatory actions of retinoblastoma (RB). To determine the role of loss of RB function in PDAC progression, we investigated the effects of Rb disruption during pancreatic malignant transformation initiated by oncogenic Kras. METHODS: We generated mice with pancreas-specific disruption of Rb, in the absence or presence of oncogenic Kras, to examine the role of RB in pancreatic carcinogenesis. RESULTS: In the presence of oncogenic Kras, loss of Rb from the pancreatic epithelium accelerated formation of pancreatic intraepithelial neoplasia (PanIN), increased the frequency of cystic neoplasms, and promoted rapid progression toward PDAC. Early stage cancers were characterized by acute pancreatic inflammation, associated with up-regulation of proinflammatory cytokines within the pancreas. Despite the presence of markers associated with oncogene-induced senescence, low-grade PanIN were highly proliferative and expressed high levels of p53. Pancreatic cancer cell lines derived from these mice expressed high levels of cytokines, and transcriptional activity of p53 was impaired. CONCLUSIONS: Rb encodes a tumor suppressor that attenuates progression of oncogenic Kras-induced carcinogenesis in the pancreas by mediating the senescence response and promoting activity of the tumor suppressor p53.


Subject(s)
Carcinoma in Situ/physiopathology , Cellular Senescence/physiology , Gene Deletion , Pancreatic Neoplasms/physiopathology , Precancerous Conditions/physiopathology , Proto-Oncogene Proteins p21(ras)/physiology , Retinoblastoma Protein/genetics , Retinoblastoma Protein/physiology , Adenocarcinoma/pathology , Adenocarcinoma/physiopathology , Animals , Carcinoma in Situ/pathology , Carcinoma, Pancreatic Ductal/pathology , Carcinoma, Pancreatic Ductal/physiopathology , Cell Line, Tumor , Cell Proliferation , Cell Transformation, Neoplastic/pathology , Cytokines/physiology , Disease Models, Animal , Disease Progression , Mice , Mice, Mutant Strains , Pancreatic Neoplasms/pathology , Precancerous Conditions/pathology , Proto-Oncogene Proteins p21(ras)/genetics , Tumor Suppressor Protein p53/physiology
13.
Clin Cancer Res ; 17(17): 5812-21, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21652542

ABSTRACT

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Diagnosis and management of PDAC are hampered by the absence of sensitive and specific disease biomarkers. MicroRNAs (miRNA) are noncoding regulatory RNAs involved in initiation and progression of human cancers. In this study, we sought to determine whether miR-10b could serve as a biomarker for PDAC. EXPERIMENTAL DESIGN: miRNA expression was characterized by fluorescence-based in situ hybridization using locked nucleic acid-modified DNA probes against miR-10b, miR-21, miR-155, miR-196a, and miR-210, followed by codetection of proteins by immunohistochemistry on the same tissue sections. miRNA expression in surgically resected PDAC tissues and in endoscopic ultrasonography (EUS)-guided fine-needle aspirate (EUS-FNA) samples was analyzed in cytokeratin 19 (CK19)-positive epithelial cells using optical intensity analysis. RESULTS: In 10 resected PDAC samples, miR-10b was the most frequently and consistently overexpressed miRNA among characterized miRNAs, exhibiting a four-fold increase in the cancer cells (P = 0.012). Given this preferential overexpression of miR-10b, we sought to determine whether miR-10b expression was clinically relevant. Accordingly, miR-10b expression was examined in 106 EUS-FNA samples obtained from pancreatic lesions. miR-10b expression was increased in cancer cells compared with CK19-positive epithelial cells in benign lesions (P = 0.0001). In patients with PDACs, lower levels of miR-10b were associated with improved response to multimodality neoadjuvant therapy, likelihood of surgical resection, delayed time to metastasis, and increased survival. CONCLUSION: miR-10b is a novel diagnostic biomarker for PDACs when assessing pancreatic lesions. Expression of miR-10b is predictive of response to neoadjuvant therapy and outcome in this disease.


Subject(s)
Carcinoma, Pancreatic Ductal/drug therapy , MicroRNAs/genetics , Pancreatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Biomarkers, Tumor , Carcinoma, Pancreatic Ductal/genetics , Carcinoma, Pancreatic Ductal/pathology , Female , Gene Expression Profiling , Humans , In Situ Hybridization , Male , MicroRNAs/biosynthesis , Middle Aged , Neoadjuvant Therapy , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Treatment Outcome
14.
Gut ; 60(10): 1379-88, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21471572

ABSTRACT

BACKGROUND AND AIMS: Premature intra-acinar activation of trypsinogen is widely considered key for both the initiation of acute pancreatitis and the development of chronic pancreatitis. However, the biological consequences of intracellular trypsinogen activation have not been directly examined. To do so, a new mouse model was developed. METHODS: Mice were engineered to conditionally express an endogenously activated trypsinogen within pancreatic acinar cells (PACE-tryp(on)). Hallmarks of pancreatitis were determined and findings were correlated to the level (zygosity) and extent (temporal and spatial) of conditional PACE-tryp(on) expression. Furthermore, the impact of acinar cell death in PACE-tryp(on) mice was assessed and compared with a model of selective diphtheria toxin (DT)-mediated induction of acinar apoptosis. RESULTS: Initiation of acute pancreatitis was observed with high (homozygous), but not low (heterozygous) levels of PACE-tryp(on) expression. Subtotal (maximal-rapid induction) but not limited (gradual-repetitive induction) conditional PACE-tryp(on) expression was associated with systemic complications and mortality. Rapid caspase-3 activation and apoptosis with delayed necrosis was observed, and loss of acinar cells led to replacement with fatty tissue. Chronic inflammation or fibrosis did not develop. Selective depletion of pancreatic acinar cells by apoptosis using DT evoked similar consequences. CONCLUSIONS: Intra-acinar activation of trypsinogen is sufficient to initiate acute pancreatitis. However, the primary response to intracellular trypsin activity is rapid induction of acinar cell death via apoptosis which facilitates resolution of the acute inflammation rather than causing chronic pancreatitis. This novel model provides a powerful tool to improve our understanding of basic mechanisms occurring during pancreatitis.


Subject(s)
Enzyme Activation/genetics , Gene Expression Regulation , Pancreatitis, Acute Necrotizing/genetics , RNA, Messenger/genetics , Trypsinogen/genetics , Animals , Intracellular Fluid/metabolism , Mice , Mice, Transgenic , Pancreatitis, Acute Necrotizing/enzymology , Reverse Transcriptase Polymerase Chain Reaction , Secretory Pathway , Trypsinogen/biosynthesis
15.
J Gastroenterol ; 45(8): 787-93, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20549251

ABSTRACT

Autoimmune pancreatitis (AIP) has been established as a distinct form of chronic pancreatitis that is distinguishable from other types such as alcoholic, hereditary or obstructive chronic pancreatitis. AIP seems to be a global disease, since it has been reported in many different countries, especially from Japan, USA and Europe (Germany, Italy, United Kingdom). Typical histopathological findings in the pancreas in AIP include a periductal lymphoplasmacytic infiltration with fibrosis, causing narrowing of the involved ducts. The typical clinical features include presentation with obstructive jaundice/pancreatic mass and a dramatic response to steroids. However, while the reports from Japan describe uniform changes called lymphoplasmacytic sclerosing pancreatitis (LPSP) in the pancreas from AIP patients, the reports from Europe and USA distinguish two histopathologic patterns in AIP patients: one with the characteristics of LPSP and another with slightly different histological features, called idiopathic duct centric pancreatitis (IDCP) or AIP with granulocytic epithelial lesions (GELs). This article reviews the evidence that GEL-positive AIP or IDCP is a second type of AIP, distinct from LPSP, in regard to pancreatic pathology, immunology and epidemiology.


Subject(s)
Autoimmune Diseases/physiopathology , Pancreatitis, Chronic/physiopathology , Animals , Autoimmune Diseases/epidemiology , Autoimmune Diseases/immunology , Fibrosarcoma/physiopathology , Granulocytes/metabolism , Humans , Pancreas/immunology , Pancreas/physiopathology , Pancreatitis, Chronic/epidemiology , Pancreatitis, Chronic/immunology
17.
Gastroenterology ; 137(3): 1072-82, 1082.e1-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19501586

ABSTRACT

BACKGROUND & AIMS: Differentiated pancreatic acinar cells expressing endogenous levels of mutant K-Ras do not spontaneously develop pancreatic ductal adenocarcinoma (PDAC). However, we hypothesized that acinar cells would develop PDAC in the presence of Ras activity levels mimicking those of human tumor cells. METHODS: We measured Ras activity in PDAC cells from mice and humans using a Raf pull-down assay. We compared the effects of acinar cell expression of mutant K-Ras at endogenous and elevated levels on Ras activity and on the development of PDAC. RESULTS: Ras activity was greatly elevated in PDAC cells compared with nontransformed cells expressing endogenous levels of mutant K-Ras. Expression of endogenous levels of mutant K-Ras in differentiated acinar cells resulted in moderately elevated Ras activity and in sparse murine pancreatic intraepithelial neoplasias (mPanINs) that did not spontaneously advance to PDAC unless the tumor suppressor p53 was simultaneously deleted. In contrast, expression of mutant K-Ras at higher levels generated Ras activity equal to that in PDAC. High Ras activity mimicking levels in PDAC led to acinar cell senescence and generated inflammation and fibrosis resembling the histologic features of chronic pancreatitis. With higher Ras activity in acinar cells, abundant mPanINs formed and spontaneously progressed to both cystic papillary carcinoma and metastatic PDAC. CONCLUSIONS: There is an important relationship between Ras activity levels and the progression of PDAC. Sufficient Ras activity in pancreatic acinar induces several important pancreatic disease manifestations not previously reported and supports a potential direct linkage between chronic pancreatitis, cystic papillary carcinoma, and PDAC.


Subject(s)
Carcinoma, Pancreatic Ductal/metabolism , Genes, ras/physiology , Pancreatic Neoplasms/metabolism , Pancreatitis, Chronic/metabolism , Animals , Carcinoma, Pancreatic Ductal/genetics , Carcinoma, Pancreatic Ductal/pathology , Cell Line, Tumor , Genes, ras/genetics , Humans , Mice , Mice, Transgenic , Mutation , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Pancreatitis, Chronic/genetics , Pancreatitis, Chronic/pathology
18.
Biochem Biophys Res Commun ; 382(3): 561-5, 2009 May 08.
Article in English | MEDLINE | ID: mdl-19292977

ABSTRACT

Chronic pancreatitis increases by 16-fold the risk of developing pancreatic ductal adenocarcinoma (PDAC), one of the deadliest human cancers. It also appears to accelerate cancer progression in genetically engineered mouse models. We now report that in a mouse model where oncogenic Kras is activated in all pancreatic cell types, two brief episodes of acute pancreatitis caused rapid PanIN progression and accelerated pancreatic cancer development. Thus, a brief inflammatory insult to the pancreas, when occurring in the context of oncogenic Kras(G12D), can initiate a cascade of events that dramatically enhances the risk for pancreatic malignant transformation.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/pathology , Pancreatitis/complications , Proto-Oncogene Proteins p21(ras)/biosynthesis , Animals , Disease Models, Animal , Disease Progression , Mice , Mice, Inbred Strains , Pancreatic Neoplasms/metabolism , Pancreatitis/metabolism , Pancreatitis/pathology , Proto-Oncogene Proteins p21(ras)/genetics
19.
Cancer Res ; 69(2): 422-30, 2009 Jan 15.
Article in English | MEDLINE | ID: mdl-19147554

ABSTRACT

Primary cilia have been proposed to participate in the modulation of growth factor signaling pathways. In this study, we determined that ciliogenesis is suppressed in both pancreatic cancer cells and pancreatic intraepithelial neoplasia (PanIN) lesions in human pancreatic ductal adenocarcinoma (PDAC). Primary cilia were absent in these cells even when not actively proliferating. Cilia were also absent from mouse PanIN cells in three different mouse models of PDAC driven by an endogenous oncogenic Kras allele. Inhibition of Kras effector pathways restored ciliogenesis in a mouse pancreatic cancer cell line, raising the possibility that ciliogenesis may be actively repressed by oncogenic Kras. By contrast, normal duct, islet, and centroacinar cells retained primary cilia in both human and mouse pancreata. Thus, arrested ciliogenesis is a cardinal feature of PDAC and its precursor PanIN lesions, does not require ongoing proliferation, and could potentially be targeted pharmacologically.


Subject(s)
Carcinoma, Pancreatic Ductal/pathology , Pancreatic Neoplasms/pathology , Precancerous Conditions/pathology , Animals , Carcinoma, Pancreatic Ductal/genetics , Carcinoma, Pancreatic Ductal/ultrastructure , Cell Growth Processes/physiology , Cell Line, Tumor , Centrosome/pathology , Cilia/pathology , Epithelial Cells/pathology , Genes, ras , Humans , Mice , Mice, Transgenic , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/ultrastructure , Precancerous Conditions/genetics , Precancerous Conditions/ultrastructure , Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...